Investors

ImmunoPrecise’s proprietary technologies and products are positioned on the leading edge of antibody development, innovating our industry as a single source provider of the full complement of antibody discovery platforms. As an investor in ImmunoPrecise Antibodies, you’re joining us at the forefront of new, exciting, and valuable advancements in next-generation antibody discovery.

IPA Completes Acquisition of BioStrand BV… Learn More.

ImmunoPrecise Antibodies Ltd. Stock Information

For more information, please review our Stock Quotes and Charts, Investor Presentation or visit our News Releases page.

For more information, please review our Stock Quotes and Charts, Investor Presentation or visit our News Releases page.

For more information, please review our Stock Quotes and Charts, Investor Presentation or visit our News & Releases page.

Investor Relations

For investor inquiries please contact:
investors@immunoprecise.com

ImmunoPrecise Newsletter

Check out our most recent blog post:SARS-CoV-2-targeting monoclonal antibody therapies: A complementary strategy to vaccination.

Earnings Call

The Company held an earnings conference call via webcast on March 16th, 2022. View a recording of the earnings call or view the transcript.

Sign Up for
Email Alerts

Enter your email to receive financial information by email.

french flagEligible French companies involved with us in research and development may receive a tax credit. Learn More.